Language
English
Publication Date
8-1-2023
Journal
Laryngoscope Investigative Otolaryngology
DOI
10.1002/lio2.1115
PMID
37621289
PMCID
PMC10446265
PubMedCentral® Posted Date
7-14-2023
PubMedCentral® Full Text Version
Post-print
Abstract
OBJECTIVE: Cisplatin forms the backbone of systemic chemotherapy treatment for oropharyngeal squamous cell carcinoma (OPSCC). The ideal cisplatin dosing regimen remains yet to be fully defined for achieving optimal efficacy and toxicity profiles in patients with comorbidity.
METHODS: We retrospectively reviewed oncologic and toxicity data for patients with OPSCC treated at the Michael E. DeBakey Veterans Affairs Medical Center between 2000 and 2020 who initiated curative intent, definitive chemo-radiation with one of three single agent regimens: high dose (HD) cisplatin, low dose (LD) cisplatin or cetuximab.
RESULTS: Patients with HPV-associated tumors and nonsmokers demonstrated improved overall and disease-free survival along with locoregional and distant metastatic control regardless of chemotherapy regimen. Regardless of regimen selection, patients which received a cumulative cisplatin dose ≥200 mg/m
CONCLUSIONS: Both HD and LD cisplatin regimens can be safely delivered to a Veteran OPSCC patient population which should allow for straightforward application of conclusions drawn from completed and active clinical trials testing cisplatin regimens.
LEVEL OF EVIDENCE: 4.
Keywords
cetuximab, cisplatin, creatinine, distant metastasis, locoregional recurrence, oropharyngeal squamous cell carcinoma, Veteran
Published Open-Access
yes
Recommended Citation
Soliman, Ola; Wilde, David C; Kemnade, Jan O; et al., "Deployment of Cisplatin in Veterans With Oropharyngeal Cancer: Toxicity and Impact on Oncologic Outcomes" (2023). Faculty and Staff Publications. 2826.
https://digitalcommons.library.tmc.edu/baylor_docs/2826
Included in
Medical Sciences Commons, Neoplasms Commons, Oncology Commons, Otolaryngology Commons, Otorhinolaryngologic Diseases Commons